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A B S T R A C T
Molting is an essential process in the life cycle of arthropods and is regulated by complex neuroendocrine
pathways where activation of the ecdysone receptor (EcR) plays a major role. The EcR forms a non-covalent
heterodimer with the ultraspiracle protein (USP) when activated by endogenous ecdysteroids, but can also be
activated by several insecticides and other environmental chemicals. Environmental release of exogenous che-
micals may thus represent a risk to non-target species due to phylogenetic conservation of the EcR in arthropods.
In the present study, structural analysis and homology models of the EcR from the freshwater crustacean Daphnia
magna were used to characterise the agonist binding pocket and identify amino acids responsible for differences
in agonist binding between arthropod species. The analysis showed that the binding pockets of steroidal and
non-steroidal agonists are partly overlapping, and the phylogenetically conserved Thr59 is a key residue for
binding both types of agonists. In silico site-directed mutagenesis and MM-GBSA dG calculations revealed that
Cys100 (D. magna numbering) is a structural determinant for cross species affinities. Other determinants are
Val129 for both types of agonists, Thr132 for steroidal agonists and Asp134 for non-steroidal agonists. The
present results can be used to predict cross species sensitivity for EcR agonists, and shows that homology
modelling and affinity predictions may contribute to identifying susceptible species for EcR-mediated endocrine
disruption.
1. Introduction
Endocrine disrupting chemicals (EDCs) are natural or synthetic
compounds that interfere with endogenous endocrine processes such as
hormone biosynthesis, metabolism, transport or biological function
[1,2]. The EDCs may resemble the structural and chemical properties of
endogenous hormones, which make them capable of binding to hor-
mone receptors, and activate or inhibit downstream endocrine pro-
cesses. The functional outcome of exposure to EDCs is often associated
with disruption of growth, development or reproduction [3,4]. These
features are highly favourable when the compounds are used as pesti-
cides to control pest populations, but unfortunately they are not always
species-specific and may thereby impact non-target species to cause
ecological and economic impact [5].
The ecdysone receptor (EcR) is an arthropod nuclear ecdysteroid
hormone-dependent receptor, and a molecular target for many EDCs
that structurally resemble their endogenous ligands (ecdysteroids). The
receptor is a ligand-activated transcription factor that regulates the
expression of genes essential for arthropod molting, metamorphosis and
reproduction, and is considered an ortholog of the mammalian farne-
soid X receptor (FXR) [6]. The EcR is a functional heterodimer, where
binding of an endogenous or exogenous ligand to the ligand binding
domain (LBD) induces a conformational change enabling dimerization
to the ultraspiracle protein (USP). The USP contains a DNA-binding
domain (DBD) that allows the dimer to induce gene expression and
activate downstream biological processes [7].
https://doi.org/10.1016/j.comtox.2019.100091
Received 19 September 2018; Received in revised form 20 May 2019; Accepted 3 June 2019
Abbreviations: EDCs, endocrine disrupting chemicals; EcR, the ecdysone receptor; FXR, mammalian farnesoid X receptor; LBD, ligand binding domain; DBD, DNA-
binding domain; USP, ultraspiracle protein; LBP, ligand binding pocket; AOPs, Adverse Outcome Pathways; KE, key events; MIE, molecular initiating event; AO,
adverse outcome; IATA, Integrated Approaches to Testing and Assessment; ROC, Receiver Operating Characteristic; BEDROC, Boltzmann-enhanced discrimination of
ROC; AUC, area under the curve; 20E, 20-hydroxyecdysone; Pon A, ponasterone A; MM-GBSA, molecular mechanics Generalized Born Surface area continuum
solvation
⁎ Corresponding Author.
E-mail address: linn.evenseth@uit.no (L.M. Evenseth).
Computational Toxicology 12 (2019) 100091
Available online 04 June 2019
2468-1113/ © 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
The usage of EcR agonists as pesticides in agriculture is widespread,
which has been demonstrated to be associated with disruption of
normal molting and potentially interfere with normal population dy-
namics of non-target arthropod species (See review by Song et al.,
2017a). After the release of X-ray crystal structures of the EcR from
various species, it was discovered that the receptor has two partially
overlapping ligand binding pockets (LBP), which distinguishes between
structural characteristics of steroidal and non-steroidal agonists [8–10].
The amino acid sequences of the EcR are highly conserved across ar-
thropod species, but the EcR ligands display taxon selectivity, most
likely caused by small differences in the LBP amino acid sequences
between taxa [8,11].
Characterisation of the EcR and the EcR LBP has largely been fo-
cusing on insects due to the need for developing effective insecticides
with high specificity. The knowledge of the EcR and EcR binding for
other arthropods is still limited, albeit the function of the EcR is highly
conserved across arthropods. The water flea Daphnia Magna (D. magna),
a freshwater cladoceran crustacean being a key primary consumer and
a significant component of the aquatic food chain, has emerged as a
good crustacean model due to the availability of a sequenced genome,
well-characterised biology, availability of standardised experimental
protocols and high ecological relevance [12]. Recent efforts to study
EDC-induced responses in this and other arthropod species has led to
the development of Adverse Outcome Pathways (AOPs) where inter-
ference with the EcR function and down-stream molecular events
leading to molting disruption were identified as the main toxicity
pathway [13–15]. The AOPs, which portray and evaluate available data
on the molecular initiating event (MIE) and the triggering of a series of
key events (KE) that ultimately leads to an adverse outcome (AO)
[13,16–19], rely on experimental and computational evidence to define
both the taxonomic and chemical applicability domains. Identification
of putative arthropod EDCs and target conservation (i.e. receptors)
across species are therefore considered instrumental to predict cross
species effects and assess the potential risk to non-target species. Effort
to develop in silico approaches that can rapidly and cost-efficiently
identify and prioritise EDCs for further research and regulatory efforts
is becoming increasingly important and proposed to partner with the
AOP framework to support tiered testing strategies in Integrated Ap-
proaches to Testing and Assessment (IATA) [20]. Computational ap-
proaches, such as homology modelling, in silico mutational studies,
docking and scoring and quantitative structure-activity relationship
(QSAR) can support and expand the information required for IATAs and
assist developing more quantitative prediction models such as quanti-
tative AOPs (qAOPs) [21].
In the present study, we are using a combination of amino acid
sequence analysis, homology modelling and calculations of the free
energy of binding to study the interactions of agonists with the EcR in
D. magna and assess the transferability of the binding data to EcR from
other arthropods using in silico based site-directed mutagenesis.
2. Methods
2.1. Software
Construction and refinement of homology models were performed
with MODELLER version 9.17. Evaluation of the models by docking,
scoring, Prime/MM-GBSA dG calculations and statistical evaluations by
Area Under the Curve (AUC) and the Boltzmann-enhanced dis-
crimination of ROC (BEDROC) scorings were performed with the
Schrödinger software version 17.4 [22].
2.2. Structural analysis of EcR-agonist binding patterns
Six available crystal structures of the EcR from different species co-
crystalized with different steroidal and non-steroidal agonists (Table 1)
were analysed. Amino acids within the binding pockets of steroidal and
non-steroidal agonists, and their interaction patterns (hydrogen bonds,
hydrophobic- and electrostatic interactions) with co-crystallized ago-
nists were identified. Amino acids within 6 Å from the co-crystallized
agonists were considered as relevant for facilitating binding, and con-
sidered as the LBP.
2.3. Construction of two agonist datasets
The EcR is highly flexible and adapts the chemical structure of both
steroidal and non-steroidal agonists. Two different compound datasets
were therefore generated, one with steroidal agonists and one with non-
steroidal agonists [10]. Except for 20-hydroxyecdysone (20E) and po-
nasterone A (Pon A), experimental binding data for the steroidal ago-
nists targeting the D. magna EcR was not identified in available data-
bases nor in the literature, but binding data for D. melanogaster EcR
agonists with a number of steroidal structures was identified. The
amino acid sequence identity between the EcR LBD of D. melanogaster
and D. magna was calculated to be>60% [23]. Nine D. melanogaster
steroidal agonists were considered active (IC50 < 1000 nM) and used
in our studies.
Valid experimental binding data of non-steroidal agonists towards
D. magna EcR was not identified in public databases such as ChEMBL
(https://www.ebi.ac.uk/chembl/, accessed august 2017). Non-steroidal
EcR agonists for our calculations were therefore selected based on ex-
perimental data for other arthropod species (Table 2). A total of 20 non-
steroidal agonists (IC50 < 1000 nM) were selected for studying the LBP
of non-steroidal agonists in the homology models.
The DUD-E database [24] was used to generate property-matched
assumed non-binders, referred to as decoys, for each active compound
in a ratio of 1:200 as previously recommended [25]. Decoys function as
negative controls that resemble the active ligands in the physical
chemistry, but are topologically dissimilar. All structures were prepared
using Schrödinger LigPrep [26] with a target pH of 7.4, retaining spe-
cified chiralities and generation of tautomers.
Table 1
The crystal structures selected for visual inspection and comparison of bonding
patterns in the pocket of steroid like agonists and non-steroid like agonists. The
table lists the protein databank (PDB) ID with structural resolution, specie and
annotation of co-crystalized agonist.
PDB ID Resolution (Å) Complex Agonist Ligand
Structure
Species
3IXP 2.85 BYI08346 Non-steroid Helicoverpa
armigera
1R20 3.0 BYI06830 Non-steroid Heliothis virescens
2R40 2.4 20E Steroid Heliothis virescens
1Z5X 3.07 Ponasterone A Steroid Bemisia tabaci
2NXX 2.75 Ponasterone A Steroid Tribolium
castaneum
4OZR 2.7 Metylene lactam Non-steroid Bovicola ovis
Table 2
The number of non-steroid like agonists tested for the EcR
from different species. Some agonists have been tested in
multiple species. Twenty non-steroid like agonists were in-
cluded in our studies.
Specie #Compound
Nezara viridula 2
Bombyx mori 12
Spodoptera littoralis 8
Heliothis virescence 1
Drosophila melanogaster 13
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2.4. Construction of and validation of homology models
The complete amino acid sequence of the D. magna EcR LBD was
obtained from the Uniprot database [27]. Two templates were identi-
fied from the Protein Data Bank (PDB) based on sequence identity with
the target (D. magna EcR), and used to construct the homology models.
The selected templates were the EcR LBD from Bemisia tabaci co-crys-
talized with 20E (PDB id: 1Z5X), and the EcR LBD from Heliothis vir-
escens co-crystallized with the non-steroidal agonist BYI06830 (PDB id:
1R20). The MODELLER software was used to generate and refine 100
homology models per template. The software constructs the model in
three steps as described by Eswar et al., 2006: (1) Assignment of folds
by identification of similarity between templates and target, (2) Se-
quence alignment of templates and target, and (3) Construction of
homology models based on the selected templates. The models were
energetically and structurally optimized using the protein preparation
wizard in Schrödinger Maestro [22,28–30] with the OPLS3 force field.
The respective agonists and corresponding property-matched de-
coys were docked in all homology models as previously described [31].
The 100 homology models generated per template were evaluated by
their abilities to differentiate active from decoys by employing AUC and
BEDROC scoring. BEDROC addresses the “early recognition” problem
by weighting the contribution of rank to the final score by using a single
parameter called α. After docking of all active compounds and their
corresponding decoys, the compounds were ranked according to
docking score and an α value of 20 was used to ensure that the con-
tribution to the final BEDROC score came from the first ranked 8% of all
docked compounds as recommended by Truchon et al. [26]. The AUC
and BEDROC scores were calculated and used to rank and select the
best models in combination with visual inspections. Both AUC and
BEDROC give scores for the models ranging between 0 and 1, where 1
indicates a perfect model able to recognize and separate all actives from
decoys. The models were evaluated based on AUC and BEDROCK scores
and the top scoring ones were selected for in silicomutagenesis, docking
of 20E, Ponasterone A, BYI08346 and BYI06830 and Prime/MM-GBSA
calculations.
2.5. Multiple sequence alignment, docking and mutational studies
All available crystal structures of the EcR in the PDB were used for
generating a multiple sequence alignment using the Schrödinger
Maestro multiple sequence viewer. Amino acid sequences of the EcR
LBD from all the species with known EcR agonists considered as active
(IC50 < 1000 nM) were identified in Uniprot and included in the
alignment.
The amino acids within the LBPs from the structural analysis of the
X-ray structures were mapped to the other sequences of the alignment
using the multiple sequence viewer (MSV) [32]. The sequences were
renumbered according to the homology models. All amino acids within
the LBP that were different from the query sequence (D. magna) con-
tributing to differences in charge, size or polarity in the LBP were used
as a reference for in silico mutation of the D. magna sequence in the
selected homology models (Table 3). In this way, the energy con-
tributions to agonist binding caused by species-specific differences in
the LBP could be analysed. After inducing mutations, hydrogen bonds
were optimised and the protein re-minimized before performing a
docking protocol with standard precision (SP) of agonists from known
EcR X-ray structures (Table 1). However, methylene lactam was not
docked since it was found to destabilize the functional heterodimer in
solution [33], indicating putative antagonistic properties. Enhanced
sampling of conformer generation and expanded sampling for selection
of initial poses (receptor-agonist complex) were used with flexible li-
gand sampling.
During docking into mutated EcRs using standard precision, new
ligand docking poses were included in the stack of docking poses (using
Maestro Pose Viewer files) only if Coulomb and Van der Waals (VdW)
interaction energies were<0 kcal/mol and the root mean square de-
viation (RMSD) were>0.5 Å from previous poses. This procedure en-
sures the identification of conformationally different docking poses.
The molecular mechanic energies combined with Generalized Born
Surface area continuum solvation (MM-GBSA) methods [22] were used
to estimate the binding free energy (dG) of the different docking poses
in wild type EcR (D. magna) and the mutated EcR homology models.
The MM-GBSA calculates energies associated with the ligand, receptor
and the complex as well as differences in energies associated with strain
and binding [34] and approximates the relative free energy of binding
(the more negative value, the more favourable is the binding of the
ligand to the receptor). This was used to evaluate if the introduced
mutation changed the relative affinity of agonists towards the receptor.
The highest ranked docking pose in terms of binding free energy was
selected as the final and most accurate pose. The relative MM-GBSA dG
value calculated for un-mutated receptor (D. magna) upon re-docking of
steroids (20E and Pon A) and non-steroids (BYI08346 and BYI06830)
were used as a threshold to evaluate the effects of the introduced mu-
tations. The percentage change in dG of agonist binding to the mutated
receptor relative to the non-mutated was calculated and used to eval-
uate the introduced mutations and thereby the EcR agonist potential for
causing effects in other species.
3. Results
3.1. Evaluation of EcR-agonist binding patterns
The multiple sequence alignments show that the residues in the two
LBPs are well conserved between the species included in the align-
ments, but the X-ray structures show that the LBP for steroidal agonists
is different and only partially overlapping with the LBP of non-steroidal
agonists (Fig. 1, S1 and S2). The steroidal LBP is slightly bigger than the
non-steroidal pocket. In D. magna EcR homology models, the volume of
the LBP of steroidal LBP is 417.7 Å3, while that of the non-steroidal is
373 Å3. The only structural difference between Pon A and 20E is a
hydroxyl group attached to the alkyl side chain of 20E (Fig. 2).
Visual inspection of the three X-ray structures co-crystalized with
steroids, Pon A (PDB ID: 1Z5X and 2NXX) [35,36] and 20E (PDB ID:
2R40) [37], revealed that 14-OH, 20-OH and 6-oxo functional groups of
the steroids are forming hydrogen bonds with Glu23, Thr59 and Ala114
(Val114 in the structure of T. castaneum). In total, up to six different
amino acids were participating in hydrogen bonds with the steroids, but
except for Glu23, Thr59 and Ala114, the other three varied between the
complexes. The X-ray structures indicated that some of the hydroxyl
groups present in the steroids function as both hydrogen bonding do-
nors and acceptors.
Investigation of three published X-ray structures of the EcR in
complex with agonists of non-steroidal structure (PDB ID: 1R20, 3IXP
and 4OZR) [33,38] showed that the number of hydrogen bonds formed
between the agonists and the amino acids in the LBP is significantly
lower than that of steroidal agonists. BYI08346 form three hydrogen
bonds with EcR from H. armigera, while BYI06830 form two hydrogen
bonds with EcR from H. virescens, despite having equal numbers of
putative hydrogen bonding donors and acceptors. The X-ray structures
show that Thr59 and Tyr124 participate in hydrogen bonding both with
BYI08346 and BYI06830.
Interestingly, the X-ray structures indicated that Thr59 was involved
in the binding of both steroidal and non-steroidal agonists (Fig. 1) and
Thr59 was involved in hydrogen bonds in all X-ray complexes.
3.2. Construction and structural analysis of homology models
One homology model per template was selected based on the
BEDROC values, AUC and supported by visual inspection (Table 4). The
statistical analysis showed that model number 23 was the most ap-
propriate for the steroidal LBP due to an AUC value of 1 and a BEDROC
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value of 0.994, which indicates a good predictive model, and the model
was selected as the homology model to represent the steroidal LBP.
Model number 97 with an AUC value of 0.98 and a BEDROC value of
0.8 was selected to represent the non-steroidal LBP. Model 56 also had
an AUC of 0.98, but model 97 was selected based on better BEDROCK
score (Table 4 and S3).
3.3. Docking and MM-GBSA calculations
A total of 9 mutations were introduced in the steroidal and 11 in the
non-steroidal LBP of the D. magna EcR homology models based on
species differences in key amino acids of the LBP (Table 3). The co-
crystalized agonists of the studied X-ray structures were docked in the
respective homology models (non-steroids: BYI08346 and BYI06830,
steroids: ponasterone A and 20E), such that the non-steroidal agonists
were re-docked in 11 models and the steroidal ligands in 9 models.
Structural investigation of the LBPs showed that the steroidal LBP and
the non-steroidal LBP are different and partly overlapping (Fig. 1 and
Fig. 3), and that the steroidal LBP appeared to be more conserved than
the LBP for non-steroidal agonists. The dG for the receptor without
mutations was calculated to be −109.3 kcal/mol for the binding of Pon
A, −108.7 kcal/mol for 20E, −87 kcal/mol for BYI08346 and
Table 3
Amino acids within 5 Å of the agonist in the agonist LBP of known EcR X-ray structures with the corresponding amino acids in EcRs from other species with available
agonist data. Only amino acids at positions that are varying between the different species are included in the table. D. magna sequence numbering is used. All amino
acids significantly different from the D. magna sequence was mutated in the D. magna homology models.
Fig. 1. The EcR of D. magna with the binding pocket for steroid like agonists
(dark blue mesh) and the binding pocket of non-steroid like agonists (light blue
mesh) indicated. These binding pockets are only partially overlapping. Thr59 is
positioned in the overlapping area between the binding pockets. In all available
X-ray structures, this residue is observed to form hydrogen bonds with bound
agonist independent of which pocket they are located within.
Fig. 2. The structure of the agonists that were docked in the homology models
to study the effects of a various mutations. A: Ponasterone A, B: BYI08346, C:
20E, D: BYI06830.
Table 4
The 10 top ranked homology models generated from the two templates. The
Model numbering was automatically generated by MODELLER. The most op-
timal models were identified on basis of BEDROC and AUC scores (in bold).
HM steroid BEDROC (alpha
20)
AUC HM Non-
steroid
BEDROC (alpha
20)
AUC
23 0.994 1.0 56 0.7 0.98
83 0.906 0.99 97 0.802 0.98
1 0.792 0.98 39 0.613 0.96
10 0.798 0.98 40 0.628 0.95
55 0.799 0.98 44 0.581 0.94
89 0.781 0.98 69 0.514 0.94
95 0.689 0.97 49 0.734 0.93
34 0.691 0.97 15 0.741 0.93
80 0.559 0.96 31 0.761 0.931
70 0.553 0.96 43 0.560 0.931
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−86.2 kcal/mol for BYI06830. These values were used as thresholds for
evaluating effects of the introduced mutations and thereby assess the
putative potential for EcR-mediated effects in other species.
3.4. Mutation in the steroidal binding pocket
The introduced mutations affected the two steroids differently, but
the mutations did not dramatically change the free energy associated
with steroidal binding. In total, only two of the mutations, Cys100Val
and Val129Met, had a clear increase in dG for Pon A to a weaker
binding energy, with changes between 16 and 17% compared to the dG
of the non-mutated receptor due to change in the interaction pattern
(Figs. 4–6). Mutation Cys100Val changed the dG by approximately 7%
for 20E, while the Val129Met mutation changed dG with approximately
12% (Figs. 4 and 5). These mutations also had the biggest impact on the
binding of 20E of all mutations. The mutation of Cys100Met gave si-
milar results for both ligands, whereas dG for Pon A increased by 5.2%
and for 20E with 6.2% into weaker binding than that observed in the
non-mutated EcR (Figs. 4 and 5).
Compared with the non-mutated EcR, the mutations Gln24His,
Thr132Asn and Lys228Gln all favourably decreased dG with 7.6–10%
for 20E (stronger binding than to the non-mutated receptor), but with
only 0.3–1.2% increase for Pon A (Fig. 4). The mutation Thr132Val
slightly affected Pon A binding compared to the non-mutated receptor,
as the decrease in dG was approximately 2%. The decrease in dG for
20E for Thr132Val was into 8.5% stronger binding than in the non-
mutated EcR.
The LBP for steroidal agonists in D. magna EcR contains an aspartic
acid (Asp23) and a threonine (Thr66) that are unique for this species,
while the other examined species contains a glutamic acid and an iso-
leucine at these positions (Table 3). The MM-GBSA calculations showed
that the Asp23Glu slightly increased the dG for Pon A (approximately
1.9%), while we saw a decrease (approximately 5%) for 20E, compared
to the un-mutated receptor (Fig. 4). The Thr66Ile mutation did not
affect dG for Pon A, but decreased the dG for 20E compared to the un-
mutated complex giving approximately the same value as seen for the
Asp23Glu mutant (Fig. 4).
Fig. 3. The binding pocket of steroid like agonists
(light blue) and non-steroid like agonists (dark blue)
superimposed and displayed in homology model 23
with Cys100 displayed. The position of Cys100 is
similar in all the models. A) In the wild type D.
magna sequence, the polar Cys100 is in very close
proximity to the steroid binding pocket without
penetrating into the pocket. B) Cys100Met mutation
enables Met100 to infiltrate the pocket for steroid
like agonists, and is also closer to the binding pocket
for non-steroid like agonists. C) Cys100Val mutation
enables valine to penetrate the pockets with one of
the hydrophobic methyl groups of the side chain.
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Fig. 4. The calculated differences in free energies upon binding of steroid like agonists for the un-mutated wild type D. magna receptor (non) and the different
mutated receptors. Gray bars show the free energy changes upon ponasterone A binding, while black bars show the free energy changes upon 20E binding.
Fig. 5. The binding pocket for steroid like agonists in
homology model 23 with ponasterone A and 20E
superimposed at their binding sites. A) Cys100 cy-
steine is positioned 2.19 Å and 3.28 Å to the closest
ligand atom in the binding pocket and is stabilized by
hydrophobic interactions. B) Cys100Met mutation
did not interfere with the binding poses and M100 is
stabilizing the ligands due to hydrophobic forces. C)
Cys100Val is less favourable since a methyl group of
valine enters deeper into the pocket than cysteine
and comes in close proximity to the agonists. D)
Val129 stabilizes the hydrophobic carbon tail of the
steroid like agonists. E) Val129Met mutation induces
sterical clashes between the receptor and the steroid
like agonists.
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3.5. Mutations in the non-steroidal binding pocket
The Cys100Met mutant increased the dG with approximately 60%
for both non-steroidal agonists, likely due to larger sterical interference
of methionine with optimal ligand-receptor binding for non-steroids
than the cysteine (Figs. 6 and 7). Of all mutations, this mutation gave
the most dramatic changes in dG compared with the un-mutated re-
ceptor. Changing the cysteine to valine in the same position (Cy-
s100Val) increased the dG with approximately 20% for BYI06830 and
30% for BYI08346 giving weaker interactions than in the non-mutated
receptor, due to the shorter hydrophobic chain in the amino acid valine
compared to methionine (Figs. 6 and 7).
The Val129Met increased dG with 20% for BYI06830 and 40% for
BYI08346 relative to the non-mutated receptor, while the Thr132Val,
Thr132Asn and Gln231Asn increased dG by 8–12% for BYI08346 and
with 15–22% for BYI06830, respectively.
Thr66 is present in the LBP of both non-steroidal and steroidal
agonists. Mutating this residue to an isoleucine (Thr66Ile) increased the
dG of non-steroidal agonist binding by approximately 20%, thus giving
weaker binding of both the non-steroidal agonists for the Thr66Ile than
Fig. 6. The calculated differences in free energies upon binding of non-steroid like agonists for the un-mutated wild type D. magna receptor (non) and the different
mutated receptors. Black bars show the free energy changes upon binding of BYI08346, while gray bars show the free energy change upon binding of BYI06830.
Fig. 7. BYI06830 and BYI08346, superimposed in
the binding pocket of homology model 97. A) The
side chain of Cys100 in the binding of the wild type
receptor forms interactions with the non-steroid like
agonists at atomic distances of 2.78 and 3.46 Å, re-
spectively. The side chain of Cys100 is forming hy-
drogen bonds with a hydrogen in the aromatic ring
of BYI06830 and with the methyl group of
BYI08346. B) Cys100Val mutation gave similar
binding poses, but with the agonists slightly closer
to Val100 than Cys100. The atomic distance from
the agonists to the closest side chain atom was
1.93 Å for BYI06830 and 2.08 Å for BYI08346. C)
The Cys100Met mutation increased the hydro-
phobicity of the pocket and the agonists are located
closer to Met100 than Cys100 at atomic distances of
2.55 Å (BYI08346) and 2.04 Å and 2.72 Å
(BYI06830).
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for the D. magna EcR (Fig. 6). Approximately the same increase was also
observed for the Met58Ile mutant. None of these amino acids interact
directly with BYI08346 and BYI06839 and the mutation has only a
structural consequence for the LBP conformation itself (Fig. 8).
The mutation Ala133Ile gave an increase of approximately 20%.
This was not unexpected, as isoleucine contains one methyl group more
than alanine, and thereby introducing less spatial freedom in the LBP
that give unfavourable hydrophobic interactions/clashes between the
agonist and the receptor. The mutations Asp134Glu and Gln231Asn
changed dG by 10–20%, except for BYI06830 where the Asp134 was
replaced with a glutamic acid that caused a 30% increase in dG.
Independently of which of these amino acids that are present in position
134, the residue seemed to be located too distantly for direct interaction
with the non-steroidal ligands.
4. Discussion
We have used homology modelling and dG calculations by the
Prime/MM-GBSA method to evaluate the impact of amino acids sub-
stitutions within the agonist LBPs of the D. magna EcR. The amino acids
for substitution were selected based on amino acid sequence alignments
of LBDs of EcRs with known 3D structure and sequences with available
agonist binding data. In that way we can also predict the impact of EcR
agonist binding in other species than D. magna.
4.1. Selection of D. magna EcR homology models
Several of the 200 generated homology models were evaluated to be
sufficiently accurate for separating agonists from decoys. On the basis
of this evaluation, one model per template was selected for mutational
and docking studies. The AUC and BEDROCK scores of these models
indicated that the modelling approach provided high quality D. magna
EcR models. The top ranked models generated for steroidal agonists
(Supplementary Fig. 3) gave an AUC of 0.98, which indicates that the
model will identify steroidal agonist over the decoy molecules in the
docking process with an accuracy of 98%. The corresponding value for
the highest scoring model binding non-steroidal agonists was 100%.
This clearly shows that we have constructed highly accurate predictive
models for docking of steroidal and non-steroidal agonists. A semi-
flexible docking protocol was performed where the receptor structure
was kept rigid and agonists flexible. Enhanced sampling of the agonists
was used to increase the conformational space of the receptor-agonist
interactions, which is crucial for increasing the accuracy in the pre-
diction of poses and dG values of the agonists [39]. Alternatively,
multiple receptor models could have been used to further increase the
conformational space of the receptor-agonist complex, but since the
purpose of the study was to investigate the energy contribution by
species-specific amino acids in the LBP, it was not considered necessary.
The MM-GBSA calculations encounter the entire pocket during calcu-
lations, and not only the residues directly involved in binding.
4.2. Analyses of X-ray structures
The LBP of both steroidal and non-steroidal agonists are highly
conserved between the EcRs (Supplementary Figs. 1 and 2), and the
pattern of agonist interactions are also similar. The X-ray structures
show that three amino acids (Glu23, Thr59 and Ala114) form hydrogen
bonds with all steroidal agonists. Thr59 and Ala114 are conserved in all
EcRs of the present study and were therefore not subjected to muta-
tions. In the D. magna EcR, Glu23 is mutated to an aspartic acid
(Table 3). Aspartic acid and glutamic acid differ only by a carbon atom
in the side chain and have similar physicochemical properties, in-
dicating that the mutation should not significantly affect agonist
binding. This was also supported by the MM-GBSA calculations (Fig. 4).
Fig. 8. The binding pocket of non-steroid like ago-
nists in homology model 97 with BYI08346 and
BYI06830 superimposed at their binding sites. The
agonists are stabilized in the binding pocket by long
range hydrophobic forces. A) Met58 (wild type re-
ceptor) forms hydrophobic interactions with the
non-steroid like agonist. B) The Met58Ile mutation
slightly changes the agonist position and decreases
the interactions. C) Thr66 located at distances of
9.85 Å and 10.97 Å between the side chain and clo-
sest agonist atoms. D) Thr66Ile changes this atomic
distance to 6.34 Å and induces unfavourable inter-
actions. E) Val129 at atomic distances of 5.89 Å and
7.56 Å to the closest agonist atoms. F) Val129M
mutation indices a flip of BYI08346 and closest
agonist atoms are at atomic distances of 2.01 Å and
3.04 Å, respectively.
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Investigation of the non-steroidal LBP showed that Thr59 and
Tyr124 were interacting with the agonists in all available X-ray crystal
structures. Thr59 is located in the overlapping part of the steroidal and
non-steroidal LBP, is conserved in all the investigated sequences, and
participates in agonist interactions independent of co-crystalized ago-
nist. On the basis of this finding, it is likely that this residue is important
in facilitating agonist binding to EcRs.
4.3. Prime/MM-GBSA calculations
The dG values calculated by the Prime/MM-GBSA approach of the
Schrödinger suit does not encounter explicit water molecules or full
conformational entropy and must be considered as approximations of
the binding free energy [40]. The dG values should therefore be used
for a relative ranking. Relative ranking has been found to correlate well
with ranking based on experimental binding affinity [41,42]. Most
often, the calculated absolute values are therefore not in direct agree-
ment with experimental binding affinities, which is also shown in the
present study where the dG values (Figs. 4 and 6) are heavily over-
estimated compared with free energy of binding from experimental
studies. The dissociation constants (Ki) of Pon A for EcR from L. cuprina,
M. persicae, B. Tbaci and H. armigera were in the range of 0.5–58 nM,
while the corresponding values for 20E were in the range of 66–290 nM
[43]. Based on the Gibbs-Helmholtz equation, an experimental affinity
value of 1 nM corresponds to a free energy of binding of approximately
−9 kcal/mol, while a value of 1 μM corresponds to approximately
−6 kcal/mol. A mutation reducing the affinity from the nM range to
the μM range should therefore increase the free energy of binding by
approximately 30%, while reducing the affinity from the μM to the mM
range would require an increase in free energy by approximately 50%.
4.4. In silico mutational studies
The evaluation of the prediction performance indicated that we
have generated high quality models that can be used to study the
binding of both steroidal and non-steroidal agonists to the D. magna
EcR. The models are also in a quality to be used for in silicomutagenesis
in order to study the differences in EcR agonist binding between D.
magna and other species.
The investigated sequences were highly conserved between species.
The lowest identity between sequences was 67%, but more than 70%
for most of the sequences (Supporting material, Figs. S2 and S3). The
LBP consists mainly of non-polar amino acids with some polar amino
acids ensuring hydrogen bonding with hydrophilic groups on the li-
gands. A similar amino acid distribution in the LBP is described for most
nuclear receptors with known X-ray structure [44,45]. Most of the se-
quences differences between species were quite conserved and should
only induce minor changes in the LBP (e.g. mutating between hydro-
phobic amino acids). Consequently, the largest changes in dG were
found when the mutation introduced changes in the physicochemical
properties of the LBP, such as the substitution of a polar cysteine in
position 100 to nonpolar residues. Disruption of polar or nonpolar in-
teractions in addition to physical changes from small to bulky residues,
can drastically change the agonist affinity. Residues found in the ster-
oidal LBP were more conserved across species than residues in the non-
steroidal LBP, resulting in smaller mutation-specific changes compared
to the non-steroidal LBP in terms of binding free energy.
The D. magna EcR is the only among the studied EcRs that has a
cysteine at position 100. The residue in this position is involved in both
binding of steroidal and non-steroidal agonists (Fig. 3), but is not
forming any hydrogen bonds with the interrogated ligands. Interest-
ingly, introduction of a valine in this position changed the dG more
than a methionine for the steroidal agonists (Fig. 4), which was directly
the opposite for the non-steroidal LBP (Fig. 6). The most predominant
change in the steroidal binding pocket was seen for Pon A where mu-
tating the cysteine residue of the D. magna sequence to valine resulted
in a large decrease in affinity (Fig. 4). A valine in this position enters
deeper into the LBP than cysteine and introduce sterical clashes with
the steroid (Fig. 5) and thereby destabilize the binding position. In
addition, both a valine and a methionine in this position decrease the
polarity of the LBP compared with a cysteine. The mutation of Val129
into methionine also reduced the affinity of both steroidal structures for
the EcR. A methionine instead of valine in this position induces clashes
that destabilize the interactions between the ligand and the LBP. The
calculations therefore indicate that species with valine in position 100
(H. virescens, S. littoralis, B. mori) and a methionine in position 129 (S.
littoralis, D. melanogaster, N. viridula, H. virescens, B. mori T. castaneum,
B. tabaci, B. ovis) is less affected by Pon A and 20E binding than D.
magna. Introduction of valine for threonine in position 132 did not
change the dG much for Pon A and only approximately 8% for 20E. In
this case, a polar amino acid is changed to a hydrophobic residue, but
both of the agonists have their hydrophobic carbon tail positioned
against the hydrophobic side chain of valine thus reducing the effect of
this mutation.
M58I and T66I are not observed to directly interact with the ligands
in the non-steroidal binding pocket, but still these mutations increase
the dG value 20% compared with the wild type. This result may be
caused by an indirect interactions between the agonist and amino acids
in this position by stabilizing the receptor conformation and thereby the
ligand pose. When Val129 is exchanged with methionine, BYI06830
flips and positions the aromatic ring towards this amino acid instead of
the bulky methyl groups (Fig. 7). This flip seems more favourable for
hydrophobic interactions with the pocket since BYI06830 interacts
stronger than BYI08346 with the mutant. The methionine perturbs
deeper into the LBP than valine and hence destabilize the interactions.
The amino acid sequence of the EcR is highly conserved, but spe-
cies-specific differences exist and contribute to taxon-specific binding
selectivity. In the present study we have used in silico methods to study
the affinity of EcR agonists across species. In that way, we have been
able to predict the species transferability of agonist binding to EcR
across species. Largest changes in dG compared with D. magna were
seen for mutations of Cys100 both for steroids and non-steroids, but
also mutations in position 129 contribute to differences between spe-
cies.
4.5. Use of homology models for predicting EcR agonists, molecular targets
and susceptible species
The binding of ecdysteroid-mimicking EDCs to the EcRs has been
identified as the molecular initiating event (MIE) of several toxicity
pathways leading to molting disruption in arthropods [13], and a
dedicated AOP has been developed and submitted to the AOPWiki
(https://aopwiki.org/aops/4). Although the taxonomic and chemical
applicability domains of this AOP has not been fully defined, the in silico
methods described herein may facilitate the development of computa-
tional models for EcR agonist binding, identify the crucial amino acid
for ligand interactions with the LBP and predict species-specific dif-
ferences in EcR binding specificities, thus expanding both the chemical
and taxonomic applicability domains of the AOPs. The model accuracy
and speed of computation are ideally suited for more pragmatic ap-
proaches such as high-throughput screening of chemical inventories to
identify active compounds, definition of the chemical applicability
domain of an AOPs, and aid prioritising the most potent EcR binders for
more thorough experimental testing [14,15]. The detailed knowledge
generated on key amino residues in the EcR ligand-LBD interaction may
support defining the taxonomic applicability domain of an AOP and
thus form the basis for identifying species likely affected by EcR ago-
nists across a broad set of taxonomic groups [46]. It is envisioned that
combinations of in silico approaches, as demonstrated herein, and in
vitro and in vivo experimental approaches would lend them self useful
for consolidating and expanding AOPs, provide building blocks for fit-
for-purpose IATA approaches and support hazards assessments of EcR-
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mediated endocrine disruption in arthropods [17,20].
5. Conclusions
The present study applied a set of computational methods to char-
acterise the EcR agonist binding pocket in D. magna, identify amino
acids responsible for differences in agonist binding between arthropod
species, and predict the binding affinities of both endogenous and
exogenous ligands to the D. magna EcR. The multiple sequence align-
ment and structural analyses clearly showed that the steroidal and non-
steroidal LBP are only partly overlapping, and that the steroidal LBP
appear to be more conserved than the LBP for non-steroidal agonists.
Thr59 is present in both pockets and is conserved across all investigated
species. Both Thr59 and Cys100 are present both in the steroidal and
non-steroidal LBP, where in silico mutations of Cys100 were predicted
to cause the largest change to ligand binding and thus were considered
the most important determinant for binding differences among species.
In addition, sequence variations in position 129 was considered to
contribute to large variations in binding affinity across species, where
species with a methionine or a valine in position 100 and methionine in
position 129 should have lower affinity towards agonists of both ster-
oidal and non-steroidal nature, than species with cysteine and valine at
these positions, respectively. Other determinants for species differences
are Thr132 for steroidal agonists and Asp134 for non-steroidal agonists.
The model evaluation and analysis indicated that we have obtained
high quality homology models that can be used to identify potential
EcR agonists. The combination of high accuracy and speed of compu-
tation makes these models ideal to support defining the chemical and
taxonomic applicability domain of AOPs, to form building blocks of
IATAs and to support future testing and hazard assessment for EcR-
mediated endocrine disruption.
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